TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Director Purchases $22,750.00 in Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Director Mats Wahlstrom acquired 5,000 shares of the stock in a transaction that occurred on Friday, November 22nd. The shares were bought at an average price of $4.55 per share, with a total value of $22,750.00. Following the completion of the purchase, the director now owns 15,727 shares in the company, valued at $71,557.85. The trade was a 46.61 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Mats Wahlstrom also recently made the following trade(s):

• On Wednesday, November 20th, Mats Wahlstrom purchased 2,040 shares of TriSalus Life Sciences stock. The shares were purchased at an average cost of $4.16 per share, with a total value of $8,486.40.

TriSalus Life Sciences Price Performance

NASDAQ TLSI opened at $4.25 on Thursday. TriSalus Life Sciences, Inc. has a 12 month low of $3.61 and a 12 month high of $10.42. The firm has a market capitalization of $129.58 million, a PE ratio of -1.71 and a beta of 0.49. The company’s 50 day simple moving average is $4.23 and its 200 day simple moving average is $5.48.

Hedge Funds Weigh In On TriSalus Life Sciences

Several hedge funds have recently modified their holdings of the company. Walleye Capital LLC acquired a new stake in shares of TriSalus Life Sciences in the third quarter valued at $66,000. Virtu Financial LLC bought a new stake in TriSalus Life Sciences in the third quarter worth about $92,000. Vestcor Inc acquired a new stake in TriSalus Life Sciences in the 3rd quarter valued at about $108,000. MSD Partners L.P. bought a new position in shares of TriSalus Life Sciences during the 3rd quarter valued at about $184,000. Finally, Wolverine Asset Management LLC acquired a new position in shares of TriSalus Life Sciences in the 2nd quarter worth approximately $240,000. 2.58% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on TLSI shares. Oppenheimer began coverage on shares of TriSalus Life Sciences in a report on Monday, September 16th. They issued an “outperform” rating and a $10.00 price objective on the stock. Northland Capmk upgraded shares of TriSalus Life Sciences to a “strong-buy” rating in a research note on Friday, October 25th. Roth Capital upgraded TriSalus Life Sciences to a “strong-buy” rating in a research report on Monday, November 11th. Canaccord Genuity Group lowered their target price on TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating on the stock in a research report on Friday, November 15th. Finally, Roth Mkm started coverage on TriSalus Life Sciences in a research note on Monday, November 11th. They set a “buy” rating and a $11.00 target price on the stock. Six research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, TriSalus Life Sciences has a consensus rating of “Buy” and a consensus target price of $12.08.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.